Marea to present MAR001 trial data at AHA conference
Marea Therapeutics will showcase Phase 2b trial results for MAR001 at the American Heart Association meeting in November 2026. The monoclonal antibody targets ANGPTL4 to lower triglycerides and enhance lipoprotein lipase activity. MAR001 has already progressed through Phase 1 and 2a development stages.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
